ObjectiveTo evaluate the clinical effect of sulfasalazine capsulae enterosolubilis with Yunnanbaiyao for ulcerative colitis. MethodsSixty patients with ulcerative colitis were randomly divided into two groups,thirty cases in treatment group and thirty cases in control group. Patients in treatment group received sulfasalazine capsulae enterosolubilis with Ytmnanbaiyao orally,patients in control group were given sulfasalazine capsulae enterosolubilis orally only. ResultsThe total effective rate of treatment group was 90. 0％ ,clinical recovery rate was 73.3％ ;The total effective rate of control group was 66.7％ ,clinical recovery rate was 43.3％ ,the differences was statistically significant(P ＜0.05). ConclusionThe clinical effect of sulfasalazine capsulae enterosolubilis with Yunnanbaiyao for ulcerative colitis was good,and should be used furthedy.

Objective To compare the effect of octreotide combined with omeprazole and omeprazole alone in the treament of upper gastrointestinal bleeding.Methods Clinical data of 101 patients with gastrointesinal bleeding were retrospectively analyzed.According to the treatment,the patients were divided into the observation group(56 cases) and control group(45 cases).The patients in observation group were given octreotide and omeprazole,and patients in control group were given omeprazol alone.Then the results of the two groups were analyzed.Results The total effective rate of observation group was 91.07％,and was higher than that of the control group(73.33％) (x2 =5.61,P ＜0.05) ;The average hemostasis time of observation group was (15.9 ±3.9)h,and was shorter than that of the control group [(23.5 ± 4.7) h] (t =1.937,P ＜ 0.05) ; The hemoglobin level of the observation group was (116.7 ± 12.4) g/h after 72 hours treatment,and was higher than that of the control group [(91.5 ± 17.3) g/h] (t =2.013,P ＜ 0.05) ;The pH of observation group was higher than that of control group after 12h,24h,48h and 72h treatment(all P ＜ 0.05).Conclusion Octreotide combined with omeprazole is effective for upper gastrointesinal bleeding,and it can shorten the bleeding time and improve the cure rate.

Objective To investigate the relationship between single-nucleotide polymorphisms of IVS13-98G/T of human protection of telomeres 1 (hPOT1) genes and gastric cancer. Methods A total of 168 patients with gastric cancer (gastric cancer group) who had been admitted to Wuwei Cancer Hospital, Wuwei People's Hospital and Liangzhou District Hospital from December 2005 to July 2006 and 156 healthy people (control group) were genotyped by polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism (PCR-RFLP) method, and the relationship between the distribution of genotypes and the risk faetors of gastric cancer was analyzed. The distribution of genotypes and allele frequency between the 2 groups were compared by chi-square test. Hardy-weinberg equilibrium test was adopted to determine whether the distribution of genotypes and allele frequency were representative. Relative risk and 95% confidence interval were calculated by non-conditional Logistic regression model. Results The frequencies of genotypes GG, GT and TT of hPOT1IVS13-98 G/T were 21.4%, 41.7% and 36.9% in gastric cancer group, and 24.4%, 51.9% and 23.7% in control group. The allele frequencies of G- and T-allele were 42.3%, 57.7% in gastric cancer group, and 49.7%, 50.3% in control group. There was no significant difference in allele frequencies of G- and T-allele between the 2 groups (X~2=3.58, P>0.05). Compared with genotype TT, the relative risks for GT and GG were 0.439 (95% CI: 0.251-0.767, P < 0.05) and 0.514 (95 % CI: 0.264-0.999, P=0.05). There was no influence of different genotypes of hPOT1IVS13-98 G/T, sex, smoking history, family history of cancer on gastric cancer. Conclusion Single-nucleotide polymorphisms of IVS13-98G/T of hPOT1 may be a protective factor of gastric cancer.